Search Results

1 - 10 of 60 items :

  • sustained viral response x
Clear All
Factors That Influence the Virological Response in Patients with Chronic Hepatitis C Treated with Pegylated Interferon and Ribavirin

Sustained Virological Response Rate: experience From Croatian Reference Center for Viral Hepatitis. Hepat Mon. 2011;11(12):986-992. 25. European Association for the Study of the L. EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol. 2011;55(2):245-64. 26. Ghany MG, Nelson DR, Strader DB, et al. American Association for Study of Liver D. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology

Open access
Regression of alveolar echinococcosis after chronic viral hepatitis C treatment with pegylated interferon alpha 2a

., Porubcová, J., Ševčíková, Z. (2009): Immune response of mice with alveolar echinococcosis to therapy with transfer factor, alone and in combination with albendazole. Parasitol. Res., 105(4): 1067–1076. DOI: 10.1007/s00436-009-1520-z [7] Dubinský, P., Svobodová, V., Turčeková, Ľ., Literák, I., Martínek, K., Reiterová, K., Kolářová, L., Klimesš, J., Mrlík, V. (1999): Echinococcus multilocularis in Slovak Republic: The first record in red foxes (Vulpes vulpes). Helminthologia, 36(2): 105

Open access
The Predictive Value of On-treatment Virological Response for Sustained Virological Response in Chronic Hepatitis C Patients Receiving a Personalized Treatment Program

, Antonaci S. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response. J Viral Hepat 2008; 15:300-304. 36. Tsubota A, Satoh K, Aizawa M, Takamatsu S, Namiki Y, Ohkusa T, et al. Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: a pilot, randomized study. World J Gastroenterol 2008; 14:7220-7224. 37. Ferenci P, Laferl H, Scherzer TM, Gschwantler

Open access
Hepatitis C Therapy – Related Haematological Side Effects are Associated with Treatment Outcome / Hematološka Neželjena Dejstva Terapije Hepatitisa C Su Povezana Sa Ishodom Lecenja

, Wedemeyer H and Cornberg M. Treating viral hepatitis C: efficacy, side effects, and complications. Gut 2006; 55: 1350-9. 8. Pawlowska M, Pilarczyk M, Foksinska A, Smukalska E, Halota W. Hematological Adverse events and Sustained Viral Response in Children Undergoing Therapy for Chronic Hepatitis C Infection. Hepat Mon 2011; 11(12): 968-74. 9. Feuerstadt P, Bunim AL, Garcia H et al. Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients. Hepatology 2010; 51(4): 1137-43. 10

Open access
Natural history, outcome, and sustainability of treatment response in chronic viral hepatitis B: Thai multicenter study

assessment of chronic viral hepatitis. J Hepatol. 1996; 25:649-54. 28. Bonino F, Marcellin P, Lau GK, Hadziyannis S, Jin R, Piratvisuth T, et al. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAgnegative chronic hepatitis B. Gut. 2007; 56:699-705. 29. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology. 2008; 47

Open access
Non-invasive quantification of liver fibrosis regression following successful treatment of chronic hepatitis C with direct acting antivirals

clearance of hepatitis C virus infection. J Viral Hepat. 2012 Mar;19(3):173-81. DOI: 10.1111/j.1365-2893.2011.01497.x 10. Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al. Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology. 2010 Jul;139(1):120-9 e18. 11. Gheorghe L, Rugina S, Dumitru IM, Franciuc I, Martinescu A, Balas I. HLA class II alleles in Romanian patients with chronic hepatitis C

Open access
Considerations on Direct Antiviral Agent Therapy in Patients Having Chronic Hepatitis C from Constanta County


Introduction: Direct-acting antiviral agents (DAA) have a direct action in chronic hepatitis C, their addition to the standard therapy with interferon alfa2 (IFN) and ribavirin (RBV) significantly improving the sustained virologic response (SVR) in this disease. Objective: The study analyses the results of triple therapy inclduign DAA in terms of tolerability and efficiency. Material and method: We selected a lot of 24 patients who concluded the DAA administration period, being in the period of finalization of standard therapy at the time of the study. In all the patients clinical and paraclinical assesment was performed including laboratory tests, fibroscan, echography, etc.

Results: The duration of the therapy consisting in association of DAA to the standard treatment was 3 months and led to a remarkable result represented by a high rate of negativation of viremia (83.3%). Among the adverse reactions recorded, the most important were: anemia 17 patients (70.8%), leucopenia 10 patients (41.6%), thrombocitopenia 14 patients (58.3%), hyperbilirubinemia 3 patients (12,5%); hyperuricemia 8 patients (33,3%), hypocalcemia 4 patients (16.6%), loss of weight 4 patients (16,6%), anal pruritus (16,6%); among the 24 patients, 2% did not exhibit any adverse reactions.

Conclusions: Despite of the various adverse reactions recorded, the triple therapy consisting in DAA added to the standard treatment proves its utility, and the high rates of sustained viral reaction justifies its utilization. It is necessary to increase the number of patients who benefit from the advantages of triple therapy, which, after becoming larger available, could become a new standard therapy in patients with viral chronic hepatitis.

Open access
Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients

the rate of virological response in HIVHCV- coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther. 13(7), 953-957. 9. Martin-Carbonero, L., Soriano, V., Valencia, E., Garcia-Samaniego, J., Lopez, M. & Gonzalez- Lahoz, J. (2001). Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 17(16), 1467-1471. doi: 10.1089/08892220152644160. 10. Mira, J.A., Lopez-Cortes, L.F., Barreiro, P., Tural, C., Torres

Open access
Detection of anti-protease inhibitors resistance mutations in HCV strains infecting treatment-naïve chronic patients from Romania

. Simmonds P, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. ICTV Virus Taxonomy Profile: Flaviviridae. J Gen Virol. 2017;98(1):2-3. DOI: 10.1099/jgv.0.000672 5. Smith DB, Becher P, Bukh J, Gould EA, Meyers G, Monath T, et al. Proposed update to the taxonomy of the genera Hepacivirus and Pegivirus within the Flaviviridae family. J Gen Virol. 2016;97(11):2894-907. DOI: 10.1099/jgv.0.000612 6. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N

Open access
Relative share of asymptomatic forms of hepatitis a in Plovdiv region, Bulgaria

References 1. Radev M. General issues of infectious diseases. In: Iliev V, ed. Infectology. Sofi a: Professor M Drinov Publishing House; 2011;4:312 (in Bulgarian). 2. Yochev S. Viral hepatitis А. In: Yochev S, ed. Infectious diseases. Plovdiv: Raykov Press; 2007;2:122 (in Bulgarian). 3. World Health Organization. The immunological basis for immunization series. Module 18: Hepatitis A. Geneva; February 2011:3. 4. WHO. Recommended surveillance standard of acute viral hepatitis. 2002. http

Open access